Ellagic acid containing Nanostructured Lipid Carriers for topical application: a preliminary study

Ellagic acid (EA) is a potent antioxidant substance of natural origin characterized by poor biopharmaceutical properties and low solubility in water that limit their use. The aim of the present study was to develop lipid based nanoparticle formulations able to encapsulate EA for dermal delivery purpose. The EA-loaded nanoparticles were prepared using two different lipid compositions, namely tristearin/tricaprylin (NLC-EA1) and tristearin/labrasol (NLC-EA2). The influence of formulations on size, entrapment efficiency and stability of EA-loaded nanoparticles was investigated. Cryo-TEM and SAXS analysess showed that no morphological differences are evident among all the types of loaded and unloaded NLC. The macroscopic aspect of both NLC-EA1 and NLC-EA2 did not change by time. No difference in size is appreciable between empty and drug-containing NLC, thus the nanoparticle diameter is not affected by the presence EA and in general no variations of the diameters occur during time. The percentage of entrapment efficiency of both EA-loaded nanoparticles was almost quantitative. In addition NLC-EA1 maintain EA stability for almost 2 months, while NLC-EA2 up to 40 days. FRAP assay showed an antioxidant activity around 60% for both the loaded NLC, as compared to the solution. Although both types of NLC are characterized by some toxicity, NLC-EA1 are less cytotoxic than NLC-EA2. Taken together these results demonstrated that the inclusion of EA within NLC could improve the water solubility, allowing for a reduction of the dosage. Moreover, the maintaining of high antioxidant effect and low toxicity were evidenced for both types of NLC-EA

Dissolved Inorganic Nutrients in the Western Mediterranean Sea (2004-2017)

Abstract. Long-term time-series are a fundamental prerequisite to understand and detect climate shifts and trends. Understanding the complex interplay of changing ocean variables and the biological implication for marine ecosystems requires extensive data collection for monitoring and hypothesis testing and validation of modelling products. In marginal seas, such as Mediterranean Sea, there are still monitoring gaps, both in time and in space. To contribute filling these gaps, an extensive dataset of dissolved inorganic nutrients profiles (nitrate, NO3; phosphate, PO4 ; and silicate, SiO2) have been collected between 2004 and 2017 in the Western Mediterranean Sea and subjected to quality control techniques to provide to the scientific community a publicly available, long-term, quality controlled, internally consistent biogeochemical data product. The database includes 27 870 stations of dissolved inorganic nutrients sampled during 24 cruises, including temperature and salinity. Details of the quality control (primary and secondary quality control) applied are reported. The data are available in PANGAEA (https://doi.pangaea.de/10.1594/PANGAEA.904172, Belgacem et al. 2019) Keywords: Mediterranean Sea, Dissolved Inorganic Nutrient, biogeochemistr

Quality controlled dataset of dissolved inorganic nutrients in the western Mediterranean Sea (2004-2017) from R/V oceanographic cruises

The database includes 870 stations sampled during 24 cruises between 2004 and 2017 in the Western Mediterranean Sea mainly on board R/Vs of the Italian National Research Council. It includes bottle data combined with CTD data. In all stations, measurements were carried out with a CTD-rosette system consisting of a CTD SBE 911 plus and a General Oceanics rosette with 24 12-l Niskin Bottles at the observed depth of the bottle sample. Temperature measurements were performed with an SBE-3/F thermometer and conductivity measurements were performed with an SBE-4 sensor. The probes were calibrated before and after the cruise. Samples of nitrate, phosphate and silicate were frozen to -20°C and stored before being analysed in laboratories onshore using standard colorimetric methods. Measurements were subjected to a rigorous quality control and this dataset includes both the original dataset after primary quality control (see "Original version") and the product after secondary quality control (crossover analysis)

Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study

Background & Aims: The treatment of chronic hepatitis B infection (CHB) in children is still an area of great uncertainty. Vitamin E is an immunostimulating/antioxidant compound proven to be safe and effective for the treatment of adult CHB. The aim of this phase 2 controlled study was to evaluate the safety and efficacy of vitamin E for the treatment of paediatric HBeAg-positive CHB. Methods: Forty-six children were randomized in a 1:1 ratio to receive vitamin E at a dose of 15 mg/ kg/day (in galenic preparation) or no treatment for 12 months and were monitored for the subsequent 12 months. Clinical, biochemical, haematological and serovirological evaluations were carried out every 3 months. Results: No significant side effects were associated with the vitamin E treatment. At the end of the study, anti-HBe seroconversion was obtained in 7 of 23 (30.4%) of vitamin E-treated versus 1 of 23 (4.3%) of the control patients (P = 0.05), while a virological response (≥2 log decrease in HBV-DNA from baseline) was observed in 9 of 23 (39.1%) vs. 2 of 23 (8.7%) respectively (P = 0.035). Conclusions: Vitamin E administration for the treatment of paediatric CHB at the tested dosage has no significant side effects and may induce anti-HBe seroconversion. Vitamin E could represent a tool for the treatment of paediatric CHB

National, longitudinal NASCITA birth cohort study: prevalence of overweight at 12 months of age in children born healthy

Objective To estimate the prevalence of overweight at 12 months in an Italian birth cohort and to identify factors related to an increased likelihood of being overweight.Methods The Italian NASCITA birth cohort was analysed. Infants were classified as underweight (<5th), normal weight (5–84th) and overweight (≥85th centile) at 12 months of age according to the WHO percentiles of body mass index (BMI) and the prevalence of overweight was estimated. To test the association between the chance of being overweight and parental and newborn characteristics, and infant feeding, healthy newborns (no preterm/low birth weight and with no malformations), with appropriate-for-gestational-age birth weight were selected, and univariate and multivariate analyses were performed.Results The prevalence of overweight was 23.5% (95% CI 22.2% to 24.8%) in all cohort members with 12-month data (N=4270), and 23.1% in the appropriate-for-gestational age subsample (N=2835).A big infant appetite (OR 3.92, 95% CI 2.40 to 6.40) and living in southern Italy (OR 1.58, 95% CI 1.29 to 1.94) were the main variables associated with a greater likelihood of being overweight. Breastfeeding practice did not influence the chance of being overweight, but was associated with an increase (exclusive breast feeding for at least 6 months) or a decrease (breast feeding for at least 12 months) in BMI z score at 12 months.Conclusions The sociodemographic factors (eg, area of residence, maternal employment status) seem to be the most relevant determinants influencing the chance of being overweight at 12 months. Early interventions, with particular attention to vulnerable families, may be helpful in preventing childhood and adult obesity